CF
OBIO icon

Corebridge Financial’s Orchestra BioMed OBIO Stock Holding History

Corebridge Financial’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,030
Closed -$51.5K – 1879
2025
Q1 		$51.5K Sell
12,030
-178
-1% -$885 ﹤0.01% 2730
2024
Q4 		$48.8K Sell
12,208
-215
-2% -$1.16K ﹤0.01% 2834
2024
Q3 		$63.9K Sell
12,423
-76
-0.6% -$496 ﹤0.01% 2794
2024
Q2 		$102K Buy
+12,499
New +$72.4K ﹤0.01% 2595

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Corebridge Financial's OBIO Position: Q2 2025 in Review

Corebridge Financial sold out of Orchestra BioMed (OBIO) in Q2 2025, closing a stake of 12,030 shares — an estimated $51.5K sold.

Corebridge Financial first reported a position in OBIO in Q2 2024 and held it in 4 quarters. The position peaked at $102K in Q2 2024. 59 funds tracked by Wall St. Rank hold OBIO as of Q2 2025.

  • Corebridge Financial reported no remaining Orchestra BioMed position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 12,030 Orchestra BioMed shares in Q2 2025, an estimated $51.5K.
  • Corebridge Financial first reported a position in Orchestra BioMed in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Orchestra BioMed position peaked at $102K in Q2 2024.
  • 59 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.